Vitamin E

Generic Name: Vitamin E

Brand Names: Mvc-fluoride, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₅₀O_₂

CAS Number: 59-02-9

Unique Ingredient Identifier: N9PR3490H9

Background: In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA.

Indication: Vitamin E supplementation is indicated for treatment of vitamin E deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet.

Associated Conditions: Vitamin Deficiency

Associated Therapies: Long-chain omega-3 fatty acid supplementation, Dietary supplementation

Clinical Trials

The Effect of Vitamin E Supplementation on Hospital Stay Duration in Non-cyanotic Heart Disease Children With Lower Respiratory Tract Infections

Phase 4

Not yet recruiting

Conditions: Respiratory Disease

Interventions: Drug: Vitamin E

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Assiut University

Target Recruit Count: 260

Registration Number: NCT06926712

Role of Vitamin E in Gaucher Disease Patients

Phase 3

Completed

Conditions: Gaucher Disease

Interventions: Drug: Vitamin E

First Posted Date: 2024-01-18

Last Posted Date: 2024-01-18

Lead Sponsor: Ain Shams University

Target Recruit Count: 40

Registration Number: NCT06211478

Locations: 🇪🇬
Ain Shams University, Cairo, Abbasia, Egypt

Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris

Phase 3

Recruiting

Conditions: Psoriasis Vulgaris

Interventions: Drug: Acetyl cysteine
Drug: Vitamin E

First Posted Date: 2023-06-18

Last Posted Date: 2023-06-18

Lead Sponsor: Badr University

Target Recruit Count: 60

Registration Number: NCT05906498

Locations: 🇪🇬
Al-Haud Al-Marsoud Hospital, Cairo, Egypt

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer
Microsatellite Stable Colorectal Carcinoma

Interventions: Drug: Vitamin E
Drug: Fruquintinib
Drug: Tislelizumab

First Posted Date: 2023-03-16

Last Posted Date: 2023-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05771181

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Ketotifen in Non-Alcoholic Fatty Liver Disease Patients

Phase 4

Not yet recruiting

Conditions: Hepatic Disease

Interventions: Drug: Vitamin E
Drug: Ketotifen

First Posted Date: 2022-11-15

Last Posted Date: 2022-11-15

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT05616442

Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block.

Phase 4

Completed

Conditions: Symptomatic Irreversible Pulpitis

Interventions: Drug: Diclofenac Sodium
Drug: Piroxicam
Drug: Vitamin E
Drug: Tramadol

First Posted Date: 2022-08-05

Last Posted Date: 2022-08-05

Lead Sponsor: Farjad Zafar

Target Recruit Count: 120

Registration Number: NCT05488925

Locations: 🇵🇰
Department of Operative Dentistry, Baqai Dental College, Baqai Medical University., Karachi, Sindh, Pakistan

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

Not Applicable

Conditions: Primary Ovarian Insufficiency

Interventions: Drug: Vitamin E
Drug: Resveratrol

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 150

Registration Number: NCT05410093

Locations: 🇨🇳
B ultrasound, Nantong, Jiangsu, China

Vitamin E Efficacy in HI/HA

Phase 2

Withdrawn

Conditions: Hyperinsulinism-Hyperammonemia Syndrome

Interventions: Drug: Vitamin E

First Posted Date: 2021-08-02

Last Posted Date: 2022-12-13

Lead Sponsor: Children's Hospital of Philadelphia

Registration Number: NCT04984798

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients

Phase 4

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Vitamin E
Drug: Ursodeoxycholic acid
Drug: Pentoxifylline

First Posted Date: 2021-07-27

Last Posted Date: 2021-07-27

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 102

Registration Number: NCT04977661

Locations: 🇪🇬
Hepatology, gastroenterology and infectious diseases department at Kafrelsheikh University Hospital, Cairo, Egypt

Vitamin E Dosing Study

Phase 2

Active, not recruiting

Conditions: Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Vitamin E

First Posted Date: 2021-03-17

Last Posted Date: 2025-04-06

Lead Sponsor: Johns Hopkins Bloomberg School of Public Health

Target Recruit Count: 200

Registration Number: NCT04801849

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy